Capture Vascular Continues with New Clinical Cases for its MegaVac Mechanical Thrombectomy System

Capture Vascular, Inc. (Capture) recently completed three successful clinical cases using its proprietary MegaVacTM Mechanical Thrombectomy System-ATK.
 
The first case involved a 42-year-old male patient with a target treatment area of the right leg, above and below the knee. Overall the MegaVacTM Mechanical Thrombectomy System was noted that it worked both easy and well and the procedure was marked successful.
 
The second case involved a 62-year-old female patient with a target treatment area of the left leg above the knee. Again the system was noted as working both easy and well where the procedure was not only successful, but the MegaVacTM Mechanical Thrombectomy System exceeded expectations.
 
The third case involved a 67-year-old male patient with a target treatment area of the left leg, above and below the knee. The MegaVacTM Catheter and ThromboWireTM Clot Retractor both performed well with debris noted in the ThromboWireTM Clot Retractor after removal.
 
Capture will continue to perform clinical cases throughout the coming months as it focuses on adoption of the MegaVacTM Mechanical Thrombectomy System-ATK.
 
The recently expanded device description of the ATK builds off of Capture’s mechanical thrombectomy technology with key features such as centering and securing the occlusion funnel tip position within the vessel, in addition to being able to pass through other lesion disruptive devices through its lumen. With these updates, Capture’s MegaVacTM Mechanical Thrombectomy System-ATK can now provide proximal occlusion, a static work environment, and the removal of emboli and thrombi for even more situations.

“In working through recent clinical experiences we continually received feedback from physicians that they wanted to use Capture’s system as a proximal occlusion conduit for atherectomy systems, CTO crossing wires, balloons and stents,” says Eric Wells, CEO of Capture Vascular. “I’m particularly excited that the team was able to meet our customer’s needs and execute these device advances,” says Wells.
 
Founded in 2013, Capture’s proprietary technology includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, which makes up the MegaVacTM Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. 

--

About Capture Vascular, Inc.
Headquartered in Telluride, Colorado, Capture Vascular, Inc. is a Medical Device development company that was founded in May of 2013 to pursue the development and commercialization of innovative medical devices. Capture Vascular’s platform technology is the MegaVacTM Mechanical Thrombectomy System that offers several unique features in one simple, efficient, and effective device. Capture Vascular, Inc. is managed by Telluride Medical Partners LLC. For more information about Capture Vascular and its technology please visit www.capturevascular.com.